Severe Asthma Pipeline Analysis Report 2026

Report Coverage

The Severe Asthma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into severe asthma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Severe Asthma. The severe asthma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The severe asthma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with severe asthma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to severe asthma.

Read more about this report - Request a Free Sample

Severe Asthma Pipeline Outlook

Severe asthma is a chronic, difficult-to-control respiratory condition characterized by persistent airway inflammation, frequent exacerbations, and reduced lung function despite high-dose treatment. It occurs due to complex immune dysregulation, often involving type 2 inflammation and elevated eosinophils, leading to airway narrowing, mucus overproduction, and heightened sensitivity to environmental triggers.

Severe asthma treatment involves high-dose inhaled corticosteroids combined with long-acting bronchodilators, oral corticosteroids, and targeted biologics. Advanced therapies focus on suppressing type 2 inflammation, reducing exacerbations, and improving symptom control in refractory patients. In December 2025, GlaxoSmithKline announced United States Food and Drug Administration approval of Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype. Supported by SWIFT phase III trials, the ultra-long-acting biologic demonstrated a significant reduction in annualised exacerbations and hospitalisations with twice-yearly dosing, enhancing patient adherence and outcomes.

Severe Asthma Epidemiology

The pipeline is driven by a substantial and rising epidemiological burden, particularly in terms of incidence and disease severity. According to Adrian Paul J Rabe et al., 2023, global asthma prevalence ranges from 3.44% in Asia to 8.33% in Oceania, with approximately 26.70% of cases classified as severe asthma. As per the Asthma and Allergy Foundation of America, over 28 million individuals in the United States are affected, indicating a high incidence rate. This increasing patient population continues to support innovation and advancement in targeted therapeutic development.

Severe Asthma – Pipeline Therapeutic Assessment

Severe Asthma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 42%, covers a major share of the total severe asthma clinical trials, reflecting strong mid-stage clinical validation and a robust pipeline advancing toward commercialization. Phase III follows at 35%, indicating a significant number of late-stage candidates nearing regulatory approval. Phase IV holds 23%, supporting post-marketing expansion and real-world evidence generation. Collectively, these phases strengthen innovation, accelerate approvals, and drive sustained growth.

Severe Asthma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the severe asthma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The severe asthma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for severe asthma. Biologic drug therapies targeting inflammatory pathways are emerging as promising options in the severe asthma pipeline. For instance, tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, is under clinical evaluation for reducing steroid dependence. Additionally, benralizumab, an anti-eosinophilic agent, is being investigated to improve symptom control and reduce exacerbations, thereby enhancing patient outcomes and quality of life.

Severe Asthma Clinical Trials – Key Players

The EMR report for the severe asthma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed severe asthma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in severe asthma clinical trials:

• Generate Biomedicines
• Enveda Therapeutics
• Nanjing RegeneCore Biotech Co., Ltd.
• Pfizer
• AstraZeneca
• Upstream Bio Inc.
• Incyte Corporation
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Mabgeek Biotech. Co. Ltd.
• Keymed Biosciences Co. Ltd.

Severe Asthma – Emerging Drugs Profile

Key Questions Answered in the Severe Asthma Pipeline Insight Report

• Which companies/institutions are leading the severe asthma drug development?
• Which company is leading the severe asthma pipeline development activities?
• What is the current severe asthma commercial assessment?
• What are the opportunities and challenges present in the severe asthma pipeline landscape?
• What is the efficacy and safety profile of severe asthma pipeline drugs?
• Which company is conducting major trials for severe asthma drugs?
• Which companies/institutions are involved in severe asthma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Severe Asthma?

Reasons To Buy This Report

The Severe Asthma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for severe asthma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from essential insights into severe asthma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Asthma Spacers Market

Asthma Treatment Market

Asthma Epidemiology Forecast